Ninety-Day Overall Healthcare Reimbursements and Their Drivers for Primary Arthroscopic Bankart Repair

Background: Arthroscopic Bankart repair (ABR) is a widely performed procedure for anterior glenohumeral instability. The aim of this study was to characterize variability and identify drivers of 90-day healthcare reimbursement after primary ABR. Methods: Primary ABR patients were identified in the PearlDiver M170 database (January 2010–April 2023). Patients who were inactive within 90 days preoperatively or postoperatively or who were coded for neoplasm or infection within 90 days preoperatively were excluded. Variables analyzed included patient characteristics (age, sex, Elixhauser Comorbidity Index [ECI]), nonclinical factors (insurance plan, geographic region), postoperative events (any adverse event [AAE], emergency department [ED] visit, hospital readmission), and total 90-day reimbursements. Multivariable linear regression was conducted to identify independent predictors of reimbursement. Results: Overall, 135,144 primary ABR patients were identified, representing $596,112,149 in total reimbursements. The mean ± SD reimbursement was $4450 ± $5268. The median (25th quartile–75th quartile) reimbursement was $3192 ($1751–$5465). Variables independently associated with the greatest 90-day reimbursement were readmission (+$18060), AAE (+$1169), and ED visit ($1044). Weaker associations were observed for geographic region, ECI, and male sex ( P < 0.0001 for all). Compared with commercial insurance, Medicare (–$2072) and Medicaid (–$1371) were associated with lower reimbursement ( P < 0.0001 for both). Notably, over the course of the study period, median overall reimbursement increased from $1930 to $3540 ( P < 0.0001). Conclusion: This longitudinal, national analysis identified cost variability and key drivers related to ABR. Preventing readmissions may yield the largest cost reductions while observed disparities across insurance plans and regions highlight opportunities for standardization and equity in reimbursement.

Authors

Publication Details

Journal
JAAOS Global Research and Reviews
Published
2026-11-01
DOI
https://doi.org/10.5435/jaaosglobal-d-25-00419
Primary Topic
Shoulder Injury and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ninety-Day Overall Healthcare Reimbursements and Their Drivers for Primary Arthroscopic Bankart Repair

Bianca Audrey Duah, Mitchell J. Christiansen, Joshua G. Sanchez, Julian Smith-Voudouris et al.
JAAOS Global Research and Reviews
Shoulder Injury and Treatment
article

Ninety-Day Overall Healthcare Reimbursements and Their Drivers for Primary Arthroscopic Bankart Repair

Bianca Audrey Duah, Mitchell J. Christiansen, Joshua G. Sanchez, Julian Smith-Voudouris, Mary K. Mulcahey, Scott J. Halperin, Jonathan Newman Grauer, Katie M. Zehner
article en

Abstract

Background: Arthroscopic Bankart repair (ABR) is a widely performed procedure for anterior glenohumeral instability. The aim of this study was to characterize variability and identify drivers of 90-day healthcare reimbursement after primary ABR. Methods: Primary ABR patients were identified in the PearlDiver M170 database (January 2010–April 2023). Patients who were inactive within 90 days preoperatively or postoperatively or who were coded for neoplasm or infection within 90 days preoperatively were excluded. Variables analyzed included patient characteristics (age, sex, Elixhauser Comorbidity Index [ECI]), nonclinical factors (insurance plan, geographic region), postoperative events (any adverse event [AAE], emergency department [ED] visit, hospital readmission), and total 90-day reimbursements. Multivariable linear regression was conducted to identify independent predictors of reimbursement. Results: Overall, 135,144 primary ABR patients were identified, representing $596,112,149 in total reimbursements. The mean ± SD reimbursement was $4450 ± $5268. The median (25th quartile–75th quartile) reimbursement was $3192 ($1751–$5465). Variables independently associated with the greatest 90-day reimbursement were readmission (+$18060), AAE (+$1169), and ED visit ($1044). Weaker associations were observed for geographic region, ECI, and male sex ( P < 0.0001 for all). Compared with commercial insurance, Medicare (–$2072) and Medicaid (–$1371) were associated with lower reimbursement ( P < 0.0001 for both). Notably, over the course of the study period, median overall reimbursement increased from $1930 to $3540 ( P < 0.0001). Conclusion: This longitudinal, national analysis identified cost variability and key drivers related to ABR. Preventing readmissions may yield the largest cost reductions while observed disparities across insurance plans and regions highlight opportunities for standardization and equity in reimbursement.

JAAOS Global Research and ReviewsVol. 10(11)
Openalex Percentile: Top 9%
Shoulder Injury and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon